

What do the national data releases tell us about patients with, and services for, colorectal tumours?

COLORECTAL CANCER (CRC) IN EUROPE



SECOND BIGGEST CANCER KILLER

CRC IS THE SECOND BIGGEST CANCER KILLER IN EUROPE 215,000

215,000 ESTIMATED NUMBER OF CRC DEATHS IN EUROPE IN A YEAR



THE FOB SCREENING TEST IS COMMONLY AVAILABLE IN EUROPE AND REDUCES THE RISK OF DYING FROM CRC BY 20-30%



1 EUROPEAN DIES EVERY 3 MINUTES FROM CRC



MEN ARE LESS LIKELY THAN WOMEN TO GET SCREENED



CRC ACCOUNTS FOR 13% OF ALL CASES OF ADULT CANCER IN EUROPE ANNUALLY



STUDIES HIGHLIGHT THAT EMBARRASSMENT IS A KEY REASON FOR PEOPLE NOT GETTING SCREENED

EMBARRASSMENT



THIRD MOST COMMON CANCER IN EUROPEAN MEN



IF YOU ARE MARRIED YOU ARE MORE LIKELY TO TAKE PART IN SCREENING



SECOND MOST COMMON CANCER IN EUROPEAN WOMEN

Introduction





New cases of bowel cancer, 2011, UK



Deaths from bowel cancer, 2012, UK



Survive bowel cancer for 10 or more years, 2010-11, England and Wales




Preventable cases of bowel cancer, UK




- Bowel cancer is one of the most common types of cancer diagnosed in the UK, with around 40,000 new cases diagnosed every year.
- About one in every 20 people in the UK will develop bowel cancer during their lifetime."


Incidence of colorectal cancer has increased significantly over the last 10 years, however, the mortality rate has decreased significantly over the same time period




Colorectal cancer incidence rates have been shown to vary by ethnicity (2002-2006)




Colorectal cancer incidence is significantly higher in the most deprived quintile for men but not women



However, mortality is significantly higher in the most deprived quintile for both males and females




1-year survival from colorectal cancer has improved significantly between 2003-07 and 2008-12 for males and females.





Source: NCRAS cancerstats

The majority of colorectal diagnoses (30%) are via the 2 week wait route, however, almost a quarter are via the emergency route – this is higher for women




People in the most deprived groups, and the youngest and oldest patients are most likely to be emergency presentations







However, the proportion of emergency presentations has decreased between 2006 and 2013 and the proportion via two week wait has increased



Survival estimates for emergency presentations are significantly poorer than other routes. Screening presentations have significantly better survival




Poor survival for emergency presentations may be associated with late stage – survival for stage 4 tumours has been found to be half that of stage 1



Clinical Headline Indicators

- A number of cancer metrics per Trust for England
- Currently being worked on by NCRAS
- The indicators will be made available in the CancerStats portal
- 'Generic' indicators, applicable to all or most cancer sites
- Example:



To be followed by site-specific metrics

CHI generic indicators

Size (4.1)		
	4.1a	Diagnosed per year
Demographics (4.2)		
	4.2a	Aged 70+
	4.2b	In male patients
	4.2c	With recorded ethnicity
	4.2d	Which is in an ethnic minority group
	4.2e	With an index of multiple deprivation score of 5 (most deprived)
Casemix (4.3)		
	4.3a	With a performance status of 0-1 recorded
Process (4.4)		
	4.4a	Discussed at MDT
	4.4b	Having CNS contact recorded (codes Y1/Y2)
	4.4c	Presenting via GP referral (referral source 03)
	4.4d	Presenting via emergency referral (referral source 01, 04, 10)
Diagnostics (4.5)		
	4.5a	With a valid stage recorded
	4.5b	Having an early stage diagnosis
	4.5c	With a histological confirmed diagnosis (basis 5, 6 or 7)
Treatments (4.6)		
	4.6a	With a planned treatment intent recorded
	4.6b	With a planned treatment intent of curative
	4.6c	Entered in a clinical trial
Outcome (4.7)		
	4.7a	Died within a year of diagnosis

Cancer data sources and links

- CancerStats and CancerData
- Fingertips Public Health Profiles tool
- Health Profiles
- Local Cancer Intelligence: statistics by Clinical Commissioning Group
- Routes to diagnosis of cancer